Clinical Trials – Valvular Heart Disease
Valvulopathies
The trial will examine the benefits of dapagliflozin treatment in patients with severe aortic stenosis discharged after transcatheter aortic valve implantation (TAVI).
Inclusion criteria:
Patients with severe aortic stenosis undergoing TAVI.
Prior admission to TAVI for HF with diabetes mellitus, LVEF ≤ 40% or GFR 25-75 ml/min.
Exclusion criteria:
Allergy, intolerance or contraindication for dapagliflozin.
Concomitant treatment with iSGTL-2 or sulfonylureas.
TFG< 25ml/min/1.73 m 2
SBP < 100 mmHg or DBP < 50 mmHg
Recurrent urinary tract infections ( ≥ 2 in the last year)
Concomitant pathology that limits life expectancy to <1 year
Study published in The New England Journal of Medicine
The study studied patients who were candidates for percutaneous aortic valve implantation and had previously been anticoagulated for atrial fibrillation. They were randomized to anticoagulation with Sintrom vs. Edoxaban (a new oral anticoagulant). The objective was to assess the incidence of cardiovascular events and complications derived from anticoagulation in both groups.
It is planned to soon begin taking part in new clinical trials also aimed at expanding knowledge in cardiology and providing the best care to our patients.
